Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EBITDA (2017 - 2025)

Aclaris Therapeutics has reported EBITDA over the past 9 years, most recently at -$19.8 million for Q4 2025.

  • Quarterly results put EBITDA at -$19.8 million for Q4 2025, up 79.58% from a year ago — trailing twelve months through Dec 2025 was -$64.4 million (up 51.15% YoY), and the annual figure for FY2025 was -$64.4 million, up 51.15%.
  • EBITDA for Q4 2025 was -$19.8 million at Aclaris Therapeutics, down from -$14.5 million in the prior quarter.
  • Over the last five years, EBITDA for ACRS hit a ceiling of -$468000.0 in Q4 2023 and a floor of -$96.9 million in Q4 2024.
  • Median EBITDA over the past 5 years was -$19.9 million (2022), compared with a mean of -$23.1 million.
  • Biggest five-year swings in EBITDA: soared 98.27% in 2023 and later tumbled 20601.28% in 2024.
  • Aclaris Therapeutics' EBITDA stood at -$23.0 million in 2021, then decreased by 17.55% to -$27.1 million in 2022, then soared by 98.27% to -$468000.0 in 2023, then tumbled by 20601.28% to -$96.9 million in 2024, then surged by 79.58% to -$19.8 million in 2025.
  • The last three reported values for EBITDA were -$19.8 million (Q4 2025), -$14.5 million (Q3 2025), and -$15.4 million (Q2 2025) per Business Quant data.